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resistance on the risk of tuberculosis
infection and disease in child household
contacts: a cross sectional study
Vera Golla1, Kathryn Snow2, Anna M. Mandalakas3, H. Simon Schaaf1, Karen Du Preez1, Anneke C. Hesseling1*
and James A. Seddon1,4*Correction
After publication of the original article [1] the authors
noted that the following errors had occurred:
 The name of the author H. Simon Schaaf had been
incorrectly tagged as Simon H. Schaaf. This has been
corrected in the author list above.
 The first p value below Table 1 is listed as p < 0.011,
however it should be p < 0.01. An updated version
of this table is included with this Correction.
The original article has also been corrected.
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Table 1 Baseline characteristics in children with household multidrug-resistant tuberculosis and drug-susceptible tuberculosis
exposure
Risk factors and clinical states DS-TB exposure (n = 316) N (%) MDR-TB exposure (n = 229) N (%)
Child factors
< 1 year 48 (15.2) 50 (21.8)
1 year 66 (20.9) 41 (17.9)
2 years 71 (22.5) 44 (19.2)
3 years 73 (23.1) 56 (24.5)
4 years 58 (18.4) 38 (16.6)
Male 162 (51.3) 119 (52.2)
Black African (vs. mixed race) 52 (16.5) 101 (44.1)**
HIV-positive 1 (0.3) 8 (3.7)*
BCG scar/vaccination documented 310 (98.1) 181 (81.2)**
Previous tuberculosis treatment 8 (2.5) 21 (9.2)*
Weight for age (z-score) < −2 32 (10.1) 23 (10.1)
Sleeps in same room as TB source case 79 (25.3) 34 (15.0)**
Sleeps in same bed as TB source case 20 (6.4) 57 (25.2)**
Adult source case /household factors
Source case sputum acid-fast bacilli smear-positive 181 (62.9) 180 (80.0)**
Household tobacco smoke exposure 245 (80.4) 145 (63.3)**
Mean socioeconomic index (x/11), n (standard deviation) 4.0 (2.6) 4.1 (2.5)
Clinical states
Exposure no infection 205 (65.7) 125 (61.3)
Infection no disease 80 (25.6) 86 (38.1)*
Disease 27 (8.7) 15 (6.6)
MDR-TB Mycobacterium tuberculosis resistant to rifampicin and isoniazid (defined by line probe assay)
DS-TB Mycobacterium tuberculosis susceptible to rifampicin and isoniazid (defined by line probe assay)
p < 0.01*; p < 0.001**
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